Transarterial Chemoembolization Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma
Latest Information Update: 14 Jun 2024
At a glance
- Drugs Tislelizumab (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 07 Jun 2024 Drug donafenib has been removed from this study.
- 05 Feb 2024 New trial record